
Please try another search
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company’s products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and Detach for the treatment of diarrhea in piglets. It also develops anti-obesity project, an oral medication to assist weight reduction and control. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.
Name | Age | Since | Title |
---|---|---|---|
Rebecca Burgell | - | 2018 | Member of Product Development Advisory Board |
Barry Campbell | - | 2018 | Member of Product Development Advisory Board |
Jakob Begun | - | 2018 | Member of Product Development Advisory Board |
Simon Keely | - | 2018 | Member of Product Development Advisory Board |
Jonathan Lindh | - | 2024 | Company Secretary & Non-Executive Director |
John Michailidis | - | 2022 | Non-Executive Director |
Peter Gibson | - | 2018 | Chairman of Product Development Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review